Reviva Pharmaceuticals Hldg Inc (RVPH) Stock Price, Quote & News

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology

Sector: Healthcare

Phone: 408-501-8881

Fax: 408-904-6270

Website: www.revivapharma.com

Address:

10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States

SlothMan2025 Dec. 7 at 12:22 PM

$RVPH you may want to check out CAPS, especially at its current price, sub-$1. They just expanded their footprint to virtually all of North America. See what they have to say about it below… Low float, high beneficial ownership, institutional ownership increased ~477% last quarter, shares available to short 0, ~86% cost to borrow, nothing but loading going on here, no one’s selling… Grab a few thousand shares, whatever you’re comfortable with, f@%k around & find out. This is one that sneaks up on you, one you look back on like CTM. How did I not see that setup? https://youtu.be/G3f1ImGNg64?si=2n0chB3huF3tFbZe

1 · Reply

Moemazon Dec. 6 at 11:14 PM

$RVPH what direction is this about to explode?

0 · Reply

KingKongBundee Dec. 6 at 5:47 PM

$RVPH The 2026 setup is getting interesting… JPM just upgraded healthcare to a preferred sector. M&A is heating up, likely partly because big pharma has massive patent cliffs coming. Biotech is the #1 sector for deal activity this year. This is the exact kind of environment where late-stage CNS names get noticed. RVPH checks every box: -Best-in-class schizo Phase 3 data -NDA window (per Lax: Apr–May 2026) -Clean safety profile -CNS market starving for new options If the trend continues, 2026–27 could be a big window for real CNS assets. RVPH is one of them. https://www.jpmorgan.com/insights/markets-and-economy/top-market-takeaways/tmt-3-reasons-we-now-favor-the-health-care-sector

3 · Reply

DJORCKO Dec. 6 at 1:32 PM

$IXHL , $PSTV and $RVPH .... hold some of them and relax

0 · Reply

toedamac Dec. 5 at 11:30 PM

$RVPH how'd you vote 👀

0 · Reply

Whiskeyunderthebed Dec. 5 at 11:02 PM

$RVPH you are now saying they are "crushing it" -LOL! These are pumper words. Calm down.

0 · Reply

Whiskeyunderthebed Dec. 5 at 11:01 PM

$RVPH

0 · Reply

EyeingTheDips Dec. 5 at 10:55 PM

$RVPH @PatriotTrader17 Great thread, but let's clarify: RSUs are typically adjusted proportionally in a reverse split, just like common shares, to maintain economic value so no "surprise dilution bomb." Per standard practice and IRS rules, the number of units decreases, but value per unit increases accordingly. That said, $RVPH is crushing it and catalysts are stacking up: Pre-NDA FDA meeting this quarter on brilaroxazine for schizophrenia, NDA filing targeted Q2 2026, plus new EU patent for pulmonary fibrosis. 22% short interest? Short squeeze incoming on positive news. Bullish af! 🚀📈 #RVPH

0 · Reply

Whiskeyunderthebed Dec. 5 at 10:42 PM

$RVPH

2 · Reply

PatriotTrader17 Dec. 5 at 10:27 PM

$RVPH They assumed a Reverse Stock Split (RS) would proportionally shrink the pool of unissued/authorized RSUs the same way it does outstanding common shares—keeping the relative math clean. But nope: RSUs are typically grandfathered or adjusted differently under standard plans (per IRS rules and common practice), so the unvested pool stays fat and untouched. Post-split, when those RSUs vest, it’s like a surprise dilution bomb. This isn’t some wild conspiracy; it’s a footnoted nightmare in every equity comp 101 guide. For example, RSUs help companies defer dilution until vesting (a pro for management), but if you misforecast it, you end up needing to hike your authorized share count to cover the gap

1 · Reply

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 28, 2025, 8:00 AM EDT - 5 weeks ago

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Oct 7, 2025, 4:08 PM EDT - 2 months ago

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Sep 19, 2025, 7:01 AM EDT - 2 months ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX

Sep 18, 2025, 9:26 PM EDT - 2 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Sep 18, 2025, 4:05 PM EDT - 2 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Aug 14, 2025, 4:25 PM EDT - 4 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 26, 2025, 8:40 AM EDT - 5 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 5, 2025, 8:00 AM EDT - 6 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 2, 2025, 7:00 AM EDT - 6 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2025, 4:05 PM EDT - 7 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Mar 30, 2025, 11:30 AM EDT - 9 months ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Feb 4, 2025, 8:00 AM EST - 10 months ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 8:00 AM EST - 11 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 7, 2025, 8:00 AM EST - 11 months ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Dec 16, 2024, 5:18 PM EST - 1 year ago

Reviva Announces Proposed Public Offering

Dec 11, 2024, 3:37 PM EST - 1 year ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Nov 14, 2024, 5:25 PM EST - 1 year ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 21, 2024, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

May 29, 2024, 4:45 PM EDT - 1 year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention

May 15, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 14, 2024, 8:00 AM EDT - 1 year ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 13, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:05 AM EDT - 1 year ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present at the UBS Virtual CNS Day

Mar 7, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at the 36th Annual ROTH Conference

Feb 20, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Jan 25, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 10, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 4, 2024, 8:00 AM EST - 2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Dec 11, 2023, 8:00 AM EST - 2 years ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Nov 30, 2023, 4:05 PM EST - 2 years ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2023, 4:01 PM EST - 2 years ago

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 2, 2023, 3:11 AM EDT - 2 years ago

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

SlothMan2025 Dec. 7 at 12:22 PM

1 · Reply

Moemazon Dec. 6 at 11:14 PM

$RVPH what direction is this about to explode?

0 · Reply

KingKongBundee Dec. 6 at 5:47 PM

3 · Reply

DJORCKO Dec. 6 at 1:32 PM

$IXHL , $PSTV and $RVPH .... hold some of them and relax

0 · Reply

toedamac Dec. 5 at 11:30 PM

$RVPH how'd you vote 👀

0 · Reply

Whiskeyunderthebed Dec. 5 at 11:02 PM

$RVPH you are now saying they are "crushing it" -LOL! These are pumper words. Calm down.

0 · Reply

Whiskeyunderthebed Dec. 5 at 11:01 PM

$RVPH

0 · Reply

EyeingTheDips Dec. 5 at 10:55 PM

0 · Reply

Whiskeyunderthebed Dec. 5 at 10:42 PM

$RVPH

2 · Reply

PatriotTrader17 Dec. 5 at 10:27 PM

1 · Reply

GI197845 Dec. 5 at 10:21 PM

$RVPH Remember, during Dr.Lax Bhat's, RVPH Q meetings, he loves to frequently state "material weakness" , "material weakness" , "material weakness" and that is his way of invoking the 5th amendment so to speak as in the Safe Harbor act, which allows the BOD to lie and bankrupt shareholders, but not being honest about their true intentions of milking the biotech for as long as possible, by doing reverse split after reverse split and dilution after dilution and warrant after warrant for the fat paychecks and continued designer bags for the wife and steak, lobster, caviar and fine wine on his yacht, all the while not truly caring about improving the quality of life for schizo patients, probably cooked the books with a trial in a 3rd world country with few regulations....

1 · Reply

jgo1 Dec. 5 at 10:00 PM

$RVPH SMH, Management just figured out they did the math wrong on how a RS changes the available unused authorized shares or they just thought a RS reduced the unused shares the same way as the common shares. That makes sense why they wanted the vote to add 200 million more shares along with the RS , they just didn't know how the process works. Woops

1 · Reply

EyeingTheDips Dec. 5 at 9:41 PM

$RVPH People like you screaming “RS” like it’s a done deal but nothing is filed, nothing is approved, and they still have other options on the table. Market makers love using RS fear to shake weak hands at the bottom. I’m betting management rides upcoming catalysts instead of nuking the share structure here. Not inevitable at all… I’m holding for the move up. $RVPH

0 · Reply

EyeingTheDips Dec. 5 at 9:36 PM

$RVPH RVPH is still in the “calm before the storm” phase: the share price is drifting because the market is waiting on the upcoming FDA meeting and NDA path clarity, not because the story has changed.

0 · Reply

Rvphwatcher Dec. 5 at 9:36 PM

$RVPH reverse split coming 👀

0 · Reply

Shalleyliu Dec. 5 at 9:14 PM

$RVPH Why is the SP moving up so slow? Very frustrated. Don't know what to say.

2 · Reply

Dubbyy Dec. 5 at 9:04 PM

$RVPH belive something happen here so fast

0 · Reply

mikeash2 Dec. 5 at 8:21 PM

$RVPH What is going on here are we holding ? $RVPH ,$RYCEY ,$DVLT 👀 great for next week step up. Bags loaded and riding the waves.

1 · Reply

Frew1234 Dec. 5 at 7:46 PM

$RVPH cmon get a little weird heading into the weekend

0 · Reply

liondwag Dec. 5 at 5:12 PM

$RVPH makes me wonder if it’s a case where no big pharma has been interested in this so for or lax got offers and turned them down cause he knows he going to get a bigger pay day at some point.

2 · Reply

independence001 Dec. 5 at 4:35 PM

$RVPH Let that sink in: ABBV reportet an annual revenue of 2.7B$ for their Vraylar drug in 2023. With worse side effects and efficacy compared to Brilaroxazine:

1 · Reply

Biscuitpants Dec. 5 at 4:34 PM

$RVPH Best post I have ever seen as it relates to Reviva...extremely well thought out... https://www.reddit.com/r/pennystocks/comments/1pd66vm/dd_part_2_rvph_and_the_fda_is_it_really_gambling/

2 · Reply

Market Cap	70.89M
Revenue (ttm)	0.00
Net Income (ttm)	-29.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,423,700
Avg Vol	11,005,618
Day's Range	N/A - N/A
Shares Out	115.06M
Stochastic %K	77%
Beta	-0.02
Analysts	Strong Sell
Price Target	$5.00